Free Trial
NASDAQ:CTMX

CytomX Therapeutics Q2 2025 Earnings Report

CytomX Therapeutics logo
$2.35 +0.16 (+7.31%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.40 +0.04 (+1.91%)
As of 08/1/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.05
Beat/Miss
N/A
One Year Ago EPS
N/A

CytomX Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$19.10 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

CytomX Therapeutics Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Thursday, August 7, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

CytomX Therapeutics Earnings Headlines

Oppenheimer Begins Coverage on CytomX Therapeutics (NASDAQ:CTMX)
This Social Security Shift Could Boost Benefits by 400%
If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.
See More CytomX Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CytomX Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CytomX Therapeutics and other key companies, straight to your email.

About CytomX Therapeutics

CytomX Therapeutics (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

View CytomX Therapeutics Profile

More Earnings Resources from MarketBeat